Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method

被引:15
作者
Mayer, SP
Giamelli, J
Sandoval, C
Roach, AS
Ozkaynak, MF
Tugal, O
Rovera, G
Jayabose, S
机构
[1] New York Med Coll, Dept Pediat, Valhalla, NY USA
[2] New York Med Coll, Dept Expt Pathol, Valhalla, NY USA
[3] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA
关键词
minimal residual disease; acute lymphoblastic leukemia; quantitative PCR; primer-design;
D O I
10.1038/sj.leu.2401530
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PCR-based detection of minimal residual disease (MRD) in children with precursor B cell acute lymphoblastic leukemia (pre-B ALL) by amplification of clone-specific antigen gene rearrangements has been labor-intensive. In this study we present a simpler, yet accurate, method to assess and quantitate MRD in pediatric pre-B ALL that utilizes these markers. From the sequence of the immunoglobulin heavy chain (IgH) and T cell receptor (TcR) gene rearrangements characterized at the time of diagnosis or relapse, primers were designed and tested in a clone-specific, single-round PCR assay, then analyzed by fluorescence staining of the PCR products. The most critical step involved an adherence to a new set of guidelines for the design of clone-specific primers. Application of this method to 54 IgH and 13 TcR (nine V delta 2D delta 3 and four D delta 2-D delta 3) gene rearrangements in 47 patients resulted in an intense band within the region of the predicted molecular weight, confirming the reproducibility of the assay. Quantitative applications of the approach were examined by performing a 10-replicate limiting dilution clone-specific PCR on six diagnostic samples and an asymptotic response model of the Von Krogh form was found to fit the data well. From this model, estimation of leukemic cells of remission bone marrow samples was achieved at a detection sensitivity of 2x10(-6). The method is demonstrated on 18 patients whose marrows were prospectively analyzed during therapy. We conclude this methodology is useful in the quick and accurate assessment of MRD in children with pre-B ALL, and could be applied to other DNA quantitation assays.
引用
收藏
页码:1843 / 1852
页数:10
相关论文
共 22 条
[1]  
BIONDI A, 1992, LEUKEMIA, V6, P282
[2]   DETECTION OF MINIMAL RESIDUAL DISEASE IN ACUTE-LEUKEMIA - METHODOLOGIC ADVANCES AND CLINICAL-SIGNIFICANCE [J].
CAMPANA, D ;
PUI, CH .
BLOOD, 1995, 85 (06) :1416-1434
[3]   Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia [J].
Cavé, H ;
ten Bosch, JV ;
Suciu, S ;
Guidal, C ;
Waterkeyn, C ;
Otten, J ;
Bakkus, M ;
Thielemans, K ;
Grandchamp, B ;
Vilmer, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :591-598
[4]  
CAVE H, 1994, BLOOD, V83, P1892
[5]  
Cayuela JM, 1996, BLOOD, V88, P302
[6]   Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia [J].
Coustan-Smith, E ;
Behm, FG ;
Sanchez, J ;
Boyett, JM ;
Hancock, ML ;
Raimondi, SC ;
Rubnitz, JE ;
Rivera, GK ;
Sandlund, JT ;
Pui, CH ;
Campana, D .
LANCET, 1998, 351 (9102) :550-554
[7]   Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia [J].
Dibenedetto, SP ;
LoNigro, L ;
Mayer, SP ;
Rovera, G ;
Schiliro, G .
BLOOD, 1997, 90 (03) :1226-1232
[8]  
GRAY JW, 1990, BONE MARROW TRANSPL, V6, P14
[9]   MOLECULAR RESIDUAL DISEASE STATUS AT THE END OF CHEMOTHERAPY FAILS TO PREDICT SUBSEQUENT RELAPSE IN CHILDREN WITH B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
ITO, Y ;
WASSERMAN, R ;
GALILI, N ;
REICHARD, BA ;
SHANE, S ;
LANGE, B ;
ROVERA, G .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :546-553
[10]   AVOIDING FALSE POSITIVES WITH PCR [J].
KWOK, S ;
HIGUCHI, R .
NATURE, 1989, 339 (6221) :237-238